20/20 Biolabs

Evidence of pricing power is limited. The company is positioning as a lower‑cost alternative to ctDNA and has not demonstrated the ability to raise prices without volume loss. Gross margin improved to 41.7% in Q2 2026 on higher mix and absorption but remains far from levels indicating durable pricing power.

Without FDA authorization or broad reimbursement, price sensitivity among municipal and wellness buyers is high; serial testing cadence could create ARPU expansion if clinically validated.